Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| macrophage | 25 studies | 34% ± 18% | |
| classical monocyte | 23 studies | 32% ± 12% | |
| non-classical monocyte | 15 studies | 24% ± 9% | |
| monocyte | 13 studies | 32% ± 14% | |
| microglial cell | 10 studies | 44% ± 15% | |
| dendritic cell | 9 studies | 25% ± 9% | |
| neutrophil | 8 studies | 28% ± 7% | |
| myeloid cell | 8 studies | 37% ± 11% | |
| conventional dendritic cell | 6 studies | 24% ± 4% | |
| mononuclear phagocyte | 5 studies | 29% ± 16% | |
| type II pneumocyte | 4 studies | 27% ± 9% |
Insufficient scRNA-seq data for expression of TLR2 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| lung | 100% | 8117.93 | 576 / 578 | 95% | 21.69 | 1101 / 1155 |
| breast | 90% | 1634.31 | 411 / 459 | 94% | 12.93 | 1053 / 1118 |
| kidney | 67% | 906.96 | 60 / 89 | 94% | 14.59 | 843 / 901 |
| bladder | 86% | 1024.19 | 18 / 21 | 75% | 9.87 | 379 / 504 |
| thymus | 71% | 654.82 | 464 / 653 | 89% | 9.49 | 537 / 605 |
| esophagus | 55% | 548.48 | 795 / 1445 | 90% | 13.48 | 164 / 183 |
| uterus | 57% | 530.01 | 97 / 170 | 86% | 10.57 | 393 / 459 |
| pancreas | 46% | 423.30 | 150 / 328 | 92% | 12.85 | 163 / 178 |
| adrenal gland | 94% | 1443.78 | 243 / 258 | 43% | 3.10 | 98 / 230 |
| intestine | 76% | 833.08 | 732 / 966 | 55% | 4.80 | 291 / 527 |
| prostate | 85% | 993.93 | 208 / 245 | 43% | 2.36 | 217 / 502 |
| stomach | 58% | 623.20 | 208 / 359 | 70% | 6.06 | 199 / 286 |
| skin | 53% | 490.11 | 952 / 1809 | 75% | 9.70 | 352 / 472 |
| ovary | 44% | 368.41 | 80 / 180 | 75% | 5.97 | 322 / 430 |
| brain | 27% | 324.36 | 722 / 2642 | 81% | 13.13 | 573 / 705 |
| spleen | 100% | 7305.02 | 241 / 241 | 0% | 0 | 0 / 0 |
| liver | 60% | 765.19 | 136 / 226 | 39% | 3.14 | 160 / 406 |
| tonsil | 0% | 0 | 0 / 0 | 98% | 21.02 | 44 / 45 |
| lymph node | 0% | 0 | 0 / 0 | 97% | 19.20 | 28 / 29 |
| adipose | 96% | 2461.88 | 1150 / 1204 | 0% | 0 | 0 / 0 |
| blood vessel | 86% | 1743.17 | 1144 / 1335 | 0% | 0 | 0 / 0 |
| peripheral blood | 83% | 24686.66 | 769 / 929 | 0% | 0 | 0 / 0 |
| heart | 51% | 587.13 | 443 / 861 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 21% | 0.87 | 17 / 80 |
| muscle | 8% | 52.85 | 61 / 803 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0031663 | Biological process | lipopolysaccharide-mediated signaling pathway |
| GO_0002224 | Biological process | toll-like receptor signaling pathway |
| GO_0032722 | Biological process | positive regulation of chemokine production |
| GO_0008285 | Biological process | negative regulation of cell population proliferation |
| GO_1901224 | Biological process | positive regulation of non-canonical NF-kappaB signal transduction |
| GO_0032728 | Biological process | positive regulation of interferon-beta production |
| GO_0006954 | Biological process | inflammatory response |
| GO_0042495 | Biological process | detection of triacyl bacterial lipopeptide |
| GO_0001774 | Biological process | microglial cell activation |
| GO_0051770 | Biological process | positive regulation of nitric-oxide synthase biosynthetic process |
| GO_0070542 | Biological process | response to fatty acid |
| GO_0038124 | Biological process | toll-like receptor TLR6:TLR2 signaling pathway |
| GO_0007612 | Biological process | learning |
| GO_0071726 | Biological process | cellular response to diacyl bacterial lipopeptide |
| GO_0071727 | Biological process | cellular response to triacyl bacterial lipopeptide |
| GO_0045087 | Biological process | innate immune response |
| GO_0007165 | Biological process | signal transduction |
| GO_0051607 | Biological process | defense response to virus |
| GO_0010628 | Biological process | positive regulation of gene expression |
| GO_0032735 | Biological process | positive regulation of interleukin-12 production |
| GO_0014005 | Biological process | microglia development |
| GO_0032868 | Biological process | response to insulin |
| GO_0032289 | Biological process | central nervous system myelin formation |
| GO_0032733 | Biological process | positive regulation of interleukin-10 production |
| GO_0051092 | Biological process | positive regulation of NF-kappaB transcription factor activity |
| GO_0006955 | Biological process | immune response |
| GO_1903974 | Biological process | positive regulation of cellular response to macrophage colony-stimulating factor stimulus |
| GO_0006691 | Biological process | leukotriene metabolic process |
| GO_0050765 | Biological process | negative regulation of phagocytosis |
| GO_0007252 | Biological process | I-kappaB phosphorylation |
| GO_0032741 | Biological process | positive regulation of interleukin-18 production |
| GO_0050830 | Biological process | defense response to Gram-positive bacterium |
| GO_0071223 | Biological process | cellular response to lipoteichoic acid |
| GO_0051964 | Biological process | negative regulation of synapse assembly |
| GO_0001666 | Biological process | response to hypoxia |
| GO_0042496 | Biological process | detection of diacyl bacterial lipopeptide |
| GO_0048714 | Biological process | positive regulation of oligodendrocyte differentiation |
| GO_0032757 | Biological process | positive regulation of interleukin-8 production |
| GO_1904466 | Biological process | positive regulation of matrix metallopeptidase secretion |
| GO_0006915 | Biological process | apoptotic process |
| GO_0071221 | Biological process | cellular response to bacterial lipopeptide |
| GO_0050729 | Biological process | positive regulation of inflammatory response |
| GO_0046209 | Biological process | nitric oxide metabolic process |
| GO_0009636 | Biological process | response to toxic substance |
| GO_0034134 | Biological process | toll-like receptor 2 signaling pathway |
| GO_0032570 | Biological process | response to progesterone |
| GO_0032760 | Biological process | positive regulation of tumor necrosis factor production |
| GO_0030177 | Biological process | positive regulation of Wnt signaling pathway |
| GO_0032755 | Biological process | positive regulation of interleukin-6 production |
| GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
| GO_0071346 | Biological process | cellular response to type II interferon |
| GO_0030667 | Cellular component | secretory granule membrane |
| GO_0043235 | Cellular component | receptor complex |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0045121 | Cellular component | membrane raft |
| GO_0005794 | Cellular component | Golgi apparatus |
| GO_0009986 | Cellular component | cell surface |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0030670 | Cellular component | phagocytic vesicle membrane |
| GO_0042995 | Cellular component | cell projection |
| GO_0044297 | Cellular component | cell body |
| GO_0035355 | Cellular component | Toll-like receptor 2-Toll-like receptor 6 protein complex |
| GO_0035354 | Cellular component | Toll-like receptor 1-Toll-like receptor 2 protein complex |
| GO_0038023 | Molecular function | signaling receptor activity |
| GO_0042834 | Molecular function | peptidoglycan binding |
| GO_0038187 | Molecular function | pattern recognition receptor activity |
| GO_0044877 | Molecular function | protein-containing complex binding |
| GO_0004888 | Molecular function | transmembrane signaling receptor activity |
| GO_0035325 | Molecular function | Toll-like receptor binding |
| GO_0001540 | Molecular function | amyloid-beta binding |
| GO_0042802 | Molecular function | identical protein binding |
| GO_0042497 | Molecular function | triacyl lipopeptide binding |
| GO_0001875 | Molecular function | lipopolysaccharide immune receptor activity |
| GO_0001530 | Molecular function | lipopolysaccharide binding |
| GO_0005515 | Molecular function | protein binding |
| GO_0061809 | Molecular function | NAD+ nucleotidase, cyclic ADP-ribose generating |
| Gene name | TLR2 |
| Protein name | Toll-like receptor Toll like receptor 2 Toll-like receptor 2 Toll-like receptor 2 (Toll/interleukin-1 receptor-like protein 4) (CD antigen CD282) |
| Synonyms | TIL4 |
| Description | FUNCTION: Cooperates with LY96 to mediate the innate immune response to bacterial lipoproteins and other microbial cell wall components. Cooperates with TLR1 or TLR6 to mediate the innate immune response to bacterial lipoproteins or lipopeptides . Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. May also activate immune cells and promote apoptosis in response to the lipid moiety of lipoproteins . Recognizes mycoplasmal macrophage-activating lipopeptide-2kD (MALP-2), soluble tuberculosis factor (STF), phenol-soluble modulin (PSM) and B.burgdorferi outer surface protein A lipoprotein (OspA-L) cooperatively with TLR6 . Stimulation of monocytes in vitro with M.tuberculosis PstS1 induces p38 MAPK and ERK1/2 activation primarily via this receptor, but also partially via TLR4 . MAPK activation in response to bacterial peptidoglycan also occurs via this receptor . Acts as a receptor for M.tuberculosis lipoproteins LprA, LprG, LpqH and PstS1, some lipoproteins are dependent on other coreceptors (TLR1, CD14 and/or CD36); the lipoproteins act as agonists to modulate antigen presenting cell functions in response to the pathogen . M.tuberculosis HSP70 (dnaK) but not HSP65 (groEL-2) acts via this protein to stimulate NF-kappa-B expression . Recognizes M.tuberculosis major T-antigen EsxA (ESAT-6) which inhibits downstream MYD88-dependent signaling (shown in mouse) (By similarity). Forms activation clusters composed of several receptors depending on the ligand, these clusters trigger signaling from the cell surface and subsequently are targeted to the Golgi in a lipid-raft dependent pathway. Forms the cluster TLR2:TLR6:CD14:CD36 in response to diacylated lipopeptides and TLR2:TLR1:CD14 in response to triacylated lipopeptides . Required for normal uptake of M.tuberculosis, a process that is inhibited by M.tuberculosis LppM (By similarity). . |
| Accessions | ENST00000642700.2 D2JYJ4 A0A8D5XLR4 D2JYJ1 D2JYJ3 A0A2R8YHF6 ENST00000643501.1 A0A2R8Y4N9 ENST00000260010.6 C6KIA9 A0A0S2Z4L7 ENST00000642580.1 O60603 ENST00000646219.1 ENST00000646219.2 D2JYJ0 A0A0S2Z4S4 ENST00000646900.1 ENST00000646900.2 ENST00000643501.2 ENST00000643087.1 A0A2R8Y7R7 D2JYJ2 C6KIA6 |
